Collegium Pharmaceutical, Inc. COLL Nucynta Products — 2028
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta products — 2028.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s nucynta products — 2028?
- Collegium Pharmaceutical, Inc. (COLL) reported nucynta products — 2028 of $0 in Q1 2026.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s nucynta products — 2028?
- Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s nucynta products — 2028 has grown at a -35.8% compound annual growth rate (CAGR), from $268.72M to $110.77M.
- What does nucynta products — 2028 mean?
- The projected amortization expense for Nucynta-related intangible assets specifically for the fiscal year 2028. It serves as a component of the multi-year schedule of expected non-cash charges for the product segment.